Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis.

The results showed a trend in improving WRS score with increasing treatment durations, but no statistical difference between selegiline and placebo (after 1 month: MD −0.90, 95% CI −2.45 to 0.64, P = 0.25, I 2 = 0%; after 6 weeks: MD −0.85, 95% CI −2.16 to 0.45, P = 0.20, I 2 = 0%; after 2 months: MD −2.23, 95% CI −5.38 to 0.91, P = 0.16, I 2 = 75%) ( Figure 3 , Supplementary Figure 4 ).

also in 53,322 other papers